<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.1 20050630//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-title>Arthritis Research &#x00026; Therapy</journal-title><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">ar1802</article-id><article-id pub-id-type="pmid">16277670</article-id><article-id pub-id-type="doi">10.1186/ar1802</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A functional variant of Fc&#x003b3; receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" corresp="yes" contrib-type="author"><name><surname>Matsumoto</surname><given-names>Isao</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>ismatsu@md.tsukuba.ac.jp</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Zhang</surname><given-names>Hua</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>zhanghuajp@yahoo.co.jp</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Muraki</surname><given-names>Yoshifumi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Yoshifumi.muraki@aventis.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Hayashi</surname><given-names>Taichi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>taichi-h@md.tsukuba.ac.jp</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Yasukochi</surname><given-names>Takanori</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>ryasuk@jp-t.ne.jp</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Kori</surname><given-names>Yuko</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Yuko_KoOri@kirin.co.jp</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Goto</surname><given-names>Daisuke</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dgoto@md.tsukuba.ac.jp</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Ito</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s-ito@md.tsukuba.ac.jp</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Tsutsumi</surname><given-names>Akito</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>atsutsum@md.tsukuba.ac.jp</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Sumida</surname><given-names>Takayuki</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>tsumida@md.tsukuba.ac.jp</email></contrib></contrib-group><aff id="I1"><label>1</label>Clinical Immunology, University of Tsukuba, University of Tsukuba, Ibaraki, Japan</aff><aff id="I2"><label>2</label>PRESTO, Japan Science and Technology Agency, Saitama, Japan</aff><pub-date pub-type="ppub"><year>2005</year></pub-date><pub-date pub-type="epub"><day>11</day><month>8</month><year>2005</year></pub-date><volume>7</volume><issue>6</issue><fpage>R1183</fpage><lpage>R1188</lpage><ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/7/6/R1183"/><history><date date-type="received"><day>4</day><month>2</month><year>2005</year></date><date date-type="rev-request"><day>15</day><month>3</month><year>2005</year></date><date date-type="rev-recd"><day>4</day><month>7</month><year>2005</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2005</year></date></history><copyright-statement>Copyright &#x000a9; 2005 Matsumoto et al.; licensee BioMed Central Ltd.</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><p>Anti-glucose-6-phosphate isomerase (GPI) antibodies are known to be arthritogenic autoantibodies in K/B&#x000d7;N mice, although some groups have reported that few healthy humans retain these antibodies. The expression of Fc&#x003b3; receptors (Fc&#x003b3;Rs) is genetically regulated and has strong implications for the development of experimental arthritis. The interaction between immune complexes and Fc&#x003b3;Rs might therefore be involved in the pathogenesis of some arthritic conditions. To explore the relationship between functional polymorphisms in Fc&#x003b3;Rs (<italic>FCGR3A</italic>-158V/F and <italic>FCGR2A</italic>-131H/R) and arthritis in individuals positive for anti-GPI antibodies, we evaluated these individuals with respect to <italic>FCGR </italic>genotype. Genotyping for <italic>FCGR3A</italic>-158V/F and <italic>FCGR2A</italic>-131H/R was performed by PCR amplification of the polymorphic site, followed by site specific restriction digestion using the genome of 187 Japanese patients with rheumatoid arthritis (including 23 who were anti-GPI antibody positive) and 158 Japanese healthy individuals (including nine who were anti-GPI antibody positive). We report here on the association of <italic>FCGR3A</italic>-158V/F functional polymorphism with anti-GPI antibody positive status. Eight out of nine healthy individuals who were positive for anti-GPI antibodies possessed the homozygous, low affinity genotype <italic>FCGR3A</italic>-158F (odds ratio = 0.09, 95% confidence interval 0.01&#x02013;0.89; <italic>P </italic>= 0.0199), and probably were 'protected' from arthritogenic antibodies. Moreover, among those who were homozygous for the high affinity genotype FCGR3A-158V/V, there were clear differences in anti-human and anti-rabbit GPI titres between patients with rheumatoid arthritis and healthy subjects (<italic>P </italic>= 0.0027 and <italic>P </italic>= 0.0015, respectively). Our findings provide a molecular model of the genetic regulation of autoantibody-induced arthritis by allele-specific affinity of the Fc&#x003b3;Rs.</p></abstract></article-meta></front><body><sec><title>Introduction</title><p>Rheumatoid arthritis (RA) is a heterogeneous autoimmune disease that is characterized by chronic inflammatory polyarthritis [<xref ref-type="bibr" rid="B1">1</xref>]. One of the characteristic features of RA is the expression of several autoantibodies. The presence of such autoantibodies (e.g. rheumatoid factor [RF]), identified by screening, is commonly used as a diagnostic marker, although the pathogenic role played by autoantibodies in RA remains a mystery.</p><p>Fc&#x003b3; receptors (Fc&#x003b3;Rs) play a pivotal role in the reaction between immune complex and myeloid cells. Three Fc&#x003b3;R types have been identified in mice and humans (Fc&#x003b3;RI, Fc&#x003b3;RII and Fc&#x003b3;RIII). In mouse arthritis models, Fc&#x003b3;RIII deficient hosts exhibit resistance to collagen type II induced arthritis and anti-glucose-6-phosphate isomerase (GPI) antibody induced arthritis [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>], suggesting that Fc&#x003b3;RIII is indispensible in autoantibody dependent arthritis. In humans Fc&#x003b3;Rs are encoded by eight genes, and the genes encoding the low affinity Fc&#x003b3;Rs (<italic>FCGR2A</italic>, <italic>FCGR3A, FCGR2C</italic>, <italic>FCGR3B </italic>and <italic>FCGR2B</italic>) are located within a gene cluster on chromosome 1q22-23. Of these Fc&#x003b3;Rs, Fc&#x003b3;RIIIa and Fc&#x003b3;RIIa are known to be stimulatory receptors. Various genetic polymorphisms of these receptors were reported to be associated with several autoimmune diseases [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>], one of which is a polymorphism in <italic>FCGR3A</italic>, with either a phenylalanine (F) or a valine (V) at amino acid position 158 [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Moreover, based on findings from a co-crystalization study with IgG<sub>1 </sub>and Fc&#x003b3;RIIIa [<xref ref-type="bibr" rid="B8">8</xref>], this residue directly interacts with the lower hinge region of IgG<sub>1</sub>, suggesting strong binding between IgG<sub>1 </sub>and Fc&#x003b3;RIIIa-158V on both natural killer cells and macrophages. For <italic>FCGR2A </italic>genes, a polymorphism at position 131 (with either histidine [H] or arginine [R]) alters the ability of the receptor to bind to certain IgG subclasses [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>].</p><p>In RA patients, <italic>FCG3A</italic>-158V/F polymorphisms were reported to be frequent in UK Caucasian, North Indian and Pakistani individuals [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>], but not in Japanese, Spanish and French individuals [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. The reason for these differences between populations is unknown, although it is possible that they might depend on the prevalence in these populations of patients with autoantibody related forms of RA, in particular the prevalence of those who have pathogenic autoantibodies that directly interact with Fc&#x003b3;Rs (especially Fc&#x003b3;RIIIa).</p><p>Anti-GPI antibodies are candidate arthritogenic antibodies. In K/B&#x000d7;N mice, polyclonal or two monoclonal anti-GPI antibodies induced arthritis in several strains of mice [<xref ref-type="bibr" rid="B16">16</xref>]. Moreover, Fc&#x003b3;RIII deficient mice were resistant to anti-GPI antibody induced arthritis [<xref ref-type="bibr" rid="B3">3</xref>]. Another recent report [<xref ref-type="bibr" rid="B17">17</xref>] also confirmed that immune complex and Fc&#x003b3;RIII are essential initiators of arthritis through sequential activation of effector cells, thus giving antibodies access into the joint. In human RA, anti-GPI antibodies have frequently been detected in patients with aggressive forms of arthritis [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>], and their levels correlated significantly with extra-articular manifestations such as rheumatoid nodules, rheumatoid vasculitis and Felty's syndrome [<xref ref-type="bibr" rid="B20">20</xref>]. Moreover, a modest association of homozygosity for the <italic>FCGR3A</italic>-158V allele with RA in the nodular phenotype was suggested by Morgan and coworkers [<xref ref-type="bibr" rid="B11">11</xref>], suggesting the presence of a link between anti-GPI antibodies and <italic>FCGR3A </italic>allele. However, whether anti-GPI antibody positive status correlates with RA is a matter of controversy [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. In our assay few healthy individuals retained anti-GPI antibodies; however, we do not know whether these protective phenotypes are associated with certain human gene polymorphisms.</p><p>In order to determine the relationship between functional polymorphisms of <italic>FCGR </italic>and possible arthritogenic anti-GPI antibodies in human conditions, we examined the correlation of these polymorphisms with anti-GPI positivity.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Patients</title><p>The study was approved by the local ethics review committee and written informed consent was obtained from all participants. Blood samples were collected from 187 Japanese patients with RA (mean age 46 &#x000b1; 17 years; 33 females; mean disease duration 12.9 years [range 1&#x02013;46 years]) including four with vasculitis and three with Felty's syndrome. These patients, randomly selected from among patients visiting the clinic, were followed at University of Tsukuba Hospital. The diagnosis of RA was based on the criteria presented by the American College of Rheumatology [<xref ref-type="bibr" rid="B23">23</xref>]. In addition, 158 Japanese volunteers (mean age 30 &#x000b1; 9 years; 105 females) were recruited from our institute to serve as a healthy comparison group. All healthy individuals were free of rheumatic disease symptoms, and derived from the same geographic locations.</p></sec><sec><title>Enzyme-linked immunosorbent assay for GPI</title><p>In order to select anti-GPI antibody positive patients, we used recombinant human GPI (described in detail previously [<xref ref-type="bibr" rid="B18">18</xref>]) or rabbit muscle GPI (Sigma, St Louis, MO, USA). Both antigens were used at 5 &#x003bc;g/ml (diluted in phosphate-buffered saline [PBS]) to coat microtitre plates (12 hours, 4&#x000b0;C). After washing twice with washing buffer (0.05% Tween 20 in PBS), Block Ace (diluted 1/4 in 1 &#x000d7; PBS; Dainippon Pharmaceuticals, Osaka, Japan) was used for saturation (30 min at 37&#x000b0;C). After two washes, sera (diluted 1/50) were added and the plates were incubated for 12 hours at 4&#x000b0;C. After washing, alkaline phosphatase (AP)-conjugated anti-human IgG (Fc fragment specific; Jackson Immuno Research, West Grove, PA, USA) was added to the plate (dilution 1/1000, for 1 hour at room temperature). After three washes, colour was developed with AP reaction solution (containing 9.6% diethanol amine, 0.25 mmol/l MgCl<sub>2</sub>; pH 9.8) with AP substrate tablets (Sigma; one AP tablet per 5 ml AP reaction solution). Plates were incubated for 1 hour at room temperature, and the optical density (OD) was measured by plate spectrophotometry at 405 nm. Determinations were performed in triplicate and standardized between experiments by reference to a highly positive human anti-GPI serum. The primary reading was processed by subtracting OD readings of control wells (coated with gluthathione-S-transferase (GST) and Block Ace for recombinant GPI&#x02013;GST and rabbit GPI, respectively). The cutoff OD was calculated from the ELISA reactions of 158 healthy Japanese donors. Those who were double positive to both antigens were considered anti-GPI antibody positive. Because we used two antigens for the discrimination, the cutoff OD (mean value + 1 standard deviation) was 0.98 for human recombinant GPI and 0.64 for rabbit native GPI.</p><p>Genomic DNA was isolated from 0.5 ml anticoagulated peripheral blood, from 187 RA patients and 158 healthy individuals, by using DNA QuickII DNA purification kit (Dainippon Pharmaceuticals, Osaka, Japan). Fc&#x003b3;R polymorphisms (<italic>FCGR3A</italic>-158V/F) were identified, as described by Koene and coworkers [<xref ref-type="bibr" rid="B6">6</xref>], using a nested PCR followed by allele specific restriction enzyme digestion. For homozygous Fc&#x003b3;RIIIA-158F patients only one undigested band (94 bp) was visible. Three bands (94 bp, 61 bp and 33 bp) were seen in heterozygous individuals, whereas for homozygous Fc&#x003b3;RIIIA-158V patients only two digested bands (61 bp and 33 bp) were detected (Fig. <xref ref-type="fig" rid="F1">1a</xref>). These genotyping findings were confirmed by direct sequencing in some individuals.</p></sec><sec><title>Fc&#x003b3;RIIA-131H/R genotyping</title><p>Genotyping of Fc&#x003b3;RIIA-131H/R also consisted of PCR followed by an allele specific restriction enzyme digestion, in accordance with the method reported by Jiang and coworkers [<xref ref-type="bibr" rid="B24">24</xref>]. The <italic>FCGR2A</italic>-131H and <italic>FCGR2A</italic>-131R alleles were visualized as 337 bp and 316 bp DNA fragments, respectively (Fig. <xref ref-type="fig" rid="F1">1b</xref>). These genotyping findings were confirmed by direct sequencing in some individuals.</p></sec><sec><title>Statistical analysis</title><p>The data were analyzed using the Student's <italic>t</italic>-test and the &#x003c7;<sup>2 </sup>test, and Fisher's exact test was used when expected frequencies were lower than 5. We used Mann&#x02013;Whitney U-test to evaluate the distribution of anti-GPI antibodies in Fc&#x003b3;RIIIA-158V/V RA patients and healthy individuals. <italic>P </italic>&#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec><title>Results</title><p>Our ELISA assay is highly specific because we used recombinant bacterial human GPI and native rabbit GPI, and double positivity for the two antibodies correlated significantly with the results of western blotting to GPI [<xref ref-type="bibr" rid="B18">18</xref>]. Because two GPI antigens were used for discrimination, the cutoff value of the OD was the mean value + one standard deviation from 158 healthy individuals, estimated using ELISA. Those who were positive for both antibodies were considered to be anti-GPI antibody positive. Using these definitions, 23 (12.3%) RA patients were anti-GPI antibody positive, and nine (5.7%) healthy individuals were anti-GPI antibody positive (Fig. <xref ref-type="fig" rid="F2">2</xref>). Statistical analysis revealed a significant difference in anti-GPI antibody positivity between RA patients and healthy individuals (&#x003c7;<sup>2 </sup>= 4.438, with one degree of freedom; <italic>P </italic>= 0.0352).</p><p>To analyze whether functional <italic>FCGR </italic>polymorphisms were correlated with anti-GPI antibody positive and negative individuals, we performed <italic>FCGR </italic>genotyping. <italic>FCGR3A </italic>and <italic>FCGR2A </italic>genotypes in the control group were in Hardy&#x02013;Weinberg equilibrium. The <italic>FCGR3A</italic>-158V allele (high affinity genotype) was more frequently identified in patients with RA than in healthy individuals within the anti-GPI antibody positive population (&#x003c7;<sup>2 </sup>= 0.012, with one degree of freedom; <italic>P </italic>= 0.012; Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>). In addition, these differences were evident when individuals were categorized according to the presence or absence of these genotypes: 56.5% of patients with RA were homozygous or heterozygous with respect to <italic>FCGR3A</italic>-158V, as compared with 11.1% of healthy individuals; and 43.5% of patients with RA were homozygous with respect to <italic>FCGR3A</italic>-158F, as compared with 88.9% of healthy individuals (&#x003c7;<sup>2 </sup>= 5.42 with one degree of freedom; <italic>P </italic>&#x0003c; 0.02; Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>). Comparison of <italic>FCGR3A</italic>-158V allele frequency between RA patients and healthy individuals revealed no statistically significant difference: 48.7% of patients with RA were homozygous or heterozygous with respect to <italic>FCGR3A</italic>-158V, as compared with 42.4% of healthy individuals; and 51.3% of patients with RA were homozygous with respect to <italic>FCGR3A</italic>-158F, as compared with 57.6% of healthy individuals (&#x003c7;<sup>2 </sup>= 1.04 with one degree of freedom; <italic>P </italic>= 0.245; Table <xref ref-type="table" rid="T1">1</xref>).</p><p>Next, <italic>FCGR2A </italic>genotyping was conducted in the same cohort (Table <xref ref-type="table" rid="T1">1</xref>). In contrast to <italic>FCGR3A</italic>, the frequency of the <italic>FCGR2A</italic>-131H allele (high affinity genotype) was not significantly different between the two groups within the anti-GPI antibody positive population (&#x003c7;<sup>2 </sup>= 0.862 with one degree of freedom; <italic>P </italic>= 0.35; Tables 1<xref ref-type="table" rid="T1"/> and <xref ref-type="table" rid="T2">2</xref>). These differences were also not evident when individuals were categorized according to the presence or absence of these genotypes (<italic>P </italic>= 0.19; Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T3">3</xref>).</p><p>We also analyzed the association between Fc&#x003b3;R and other related autoantibodies such as RF. There was no difference between RF positive and RF negative populations of RA patients (<italic>P </italic>= 0.82 and <italic>P </italic>= 0.4 for <italic>FCGR3A </italic>and <italic>FCGR2A</italic>, respectively; Table <xref ref-type="table" rid="T4">4</xref>).</p><p>Finally, in order to identify the relationship between <italic>FCGR3A</italic>-158V allele and anti-GPI antibodies more clearly, we focused on individuals who were homozygous for the high affinity <italic>FCGR3A</italic>-158V/V genotype (14 RA patients and eight healthy individuals) and compared their anti-GPI antibody titres. Surprisingly, both anti-human GPI antibodies and anti-rabbit GPI antibodies were significantly elevated in the RA group (<italic>P </italic>= 0.0027 and <italic>P </italic>= 0.0015 for anti-human GPI antibodies and anti-rabbit GPI antibodies, respectively, by Mann&#x02013;Whitney U-test; Fig. <xref ref-type="fig" rid="F3">3</xref>). This suggests that anti-GPI antibody positivity might predispose individuals with the <italic>FCGR3A</italic>-158V/V genotype to arthritis.</p></sec><sec><title>Discussion</title><p>Several studies have indicated that anti-GPI antibodies are potential arthritogenic antibodies [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>] because they were frequently detected in patients with severe forms of RA. Because high titres of these antibodies (IgG, not IgM) were also detected in healthy individuals, the arthritogenicity of these antibodies should be due to modulation &#x02013; by the low affinity genotype of Fc&#x003b3;Rs &#x02013; of the bypass between immune complex and Fc&#x003b3;R bearing cells. In a GPI immunized mouse model severe arthritis occurred only in DBA/1 mice, although the production of anti-GPI antibodies was almost equal in arthritis susceptible and resistant mouse strains [<xref ref-type="bibr" rid="B25">25</xref>]. Thus, the incidence of arthritis might depend on certain genetic factors such as Fc&#x003b3;R. Anti-GPI antibody positive individuals express several GPI variant mRNAs in peripheral blood monocytes [<xref ref-type="bibr" rid="B26">26</xref>]. This observation supports the notion that the presence of GPI variants is necessary to produce anti-GPI autoantibodies, and that genetic factors such as Fc&#x003b3;RIIIA are important in the development of arthritis. Based on this conclusion, it is conceivable that the production of anti-GPI antibodies does not occur as a 'result' of joint destruction.</p><p>Our results do not indicate that individual polymorphisms in the <italic>FCGR3A </italic>and <italic>FCGR2A </italic>genes play roles in susceptibility to RA. Despite the lack of association with individual <italic>FCGR </italic>polymorphisms in the whole cohort, our studies suggest that <italic>FCGR3A</italic>-158V/F polymorphisms play a crucial role in RA among those individuals who are positive for anti-GPI antibodies (Tables <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>). Moreover, focusing on <italic>FCGR3A</italic>-158V/V homozygous individuals, anti-GPI antibodies were clearly evident in patients with RA. These findings suggest that anti-GPI antibodies might have arthritogenic potential in individuals homozygous for <italic>FCGR3A</italic>-158V/V.</p></sec><sec><title>Conclusion</title><p>Our findings show that <italic>FCGR3A</italic>-158V/F functional polymorphisms were associated with RA among anti-GPI antibody positive individuals. This is the first report on possible mechanisms of arthritic diseases; they are tightly regulated by some genes, especially by Fc&#x003b3;R genotype, as well as by production of arthritogenic autoantibodies.</p></sec><sec><title>Abbreviations</title><p>AP = alkaline phosphatase; bp = base pairs; ELISA = enzyme-linked immunosorbent assay; Fc&#x003b3;R = Fc&#x003b3; receptor; GPI = glucose-6-phosphate isomerase; GST = gluthathione-S-transferase; OD = optical density; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; RA = rheumatoid arthritis; RF = rheumatoid factor.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>IM wrote the manuscript and conceived the study. HZ performed Fc&#x003b3;R genotyping and coordinated the statistical analysis. YM, TY and YK performed GPI ELISA. TH participated in clinical assessment. TS participated in the full design and coordination of the study, and DG, SI and AT participated in writing the discussion.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported in part by the Japanese Ministry of Science and Culture (IM, TS). IM is also a recipient of a fellowship from the Japan Intractable Diseases Research Foundation, Uehara Memorial Foundation, and Japan Rheumatoid Foundation.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Firestein</surname><given-names>GS</given-names></name></person-group><article-title>Evolving concepts of rheumatoid arthritis</article-title><source>Nature</source><year>2003</year><volume>423</volume><fpage>356</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">12748655</pub-id><pub-id pub-id-type="doi">10.1038/nature01661</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diaz de Stahl</surname><given-names>T</given-names></name><name><surname>Andren</surname><given-names>M</given-names></name><name><surname>Martinsson</surname><given-names>P</given-names></name><name><surname>Verbeek</surname><given-names>JS</given-names></name><name><surname>Kleinau</surname><given-names>S</given-names></name></person-group><article-title>Expression of FcgammaRIII is required for development of collagen-induced arthritis</article-title><source>Eur J Immunol</source><year>2002</year><volume>32</volume><fpage>2915</fpage><lpage>2922</lpage><pub-id pub-id-type="pmid">12355445</pub-id><pub-id pub-id-type="doi">10.1002/1521-4141(2002010)32:10&#x0003c;2915::AID-IMMU2915&#x0003e;3.0.CO;2-4</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Ohmura</surname><given-names>K</given-names></name><name><surname>Mahmood</surname><given-names>U</given-names></name><name><surname>Lee</surname><given-names>DM</given-names></name><name><surname>Hofhuis</surname><given-names>FM</given-names></name><name><surname>Boackle</surname><given-names>SA</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Holers</surname><given-names>VM</given-names></name><name><surname>Walport</surname><given-names>M</given-names></name><name><surname>Gerard</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Arthritis critically dependent on innate immune system players</article-title><source>Immunity</source><year>2002</year><volume>16</volume><fpage>157</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">11869678</pub-id><pub-id pub-id-type="doi">10.1016/S1074-7613(02)00275-3</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dijstelbloem</surname><given-names>HM</given-names></name><name><surname>Scheepers</surname><given-names>RH</given-names></name><name><surname>Oost</surname><given-names>WW</given-names></name><name><surname>Stegeman</surname><given-names>CA</given-names></name><name><surname>van der Pol</surname><given-names>WL</given-names></name><name><surname>Sluiter</surname><given-names>WJ</given-names></name><name><surname>Kallenberg</surname><given-names>CG</given-names></name><name><surname>van de Winkel</surname><given-names>JG</given-names></name><name><surname>Tervaert</surname><given-names>JW</given-names></name></person-group><article-title>Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse</article-title><source>Arthritis Rheum</source><year>1999</year><volume>42</volume><fpage>1823</fpage><lpage>1827</lpage><pub-id pub-id-type="pmid">10513795</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(199909)42:9&#x0003c;1823::AID-ANR5&#x0003e;3.0.CO;2-X</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Myhr</surname><given-names>KM</given-names></name><name><surname>Raknes</surname><given-names>G</given-names></name><name><surname>Nyland</surname><given-names>H</given-names></name><name><surname>Vedeler</surname><given-names>C</given-names></name></person-group><article-title>Immunoglobulin G Fc-receptor (FcgammaR) IIA and IIIB polymorphisms related to disability in MS</article-title><source>Neurology</source><year>1999</year><volume>52</volume><fpage>1771</fpage><lpage>1776</lpage><pub-id pub-id-type="pmid">10371522</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koene</surname><given-names>HR</given-names></name><name><surname>Kleijer</surname><given-names>M</given-names></name><name><surname>Algra</surname><given-names>J</given-names></name><name><surname>Roos</surname><given-names>D</given-names></name><name><surname>von dem Borne</surname><given-names>AE</given-names></name><name><surname>de Haas</surname><given-names>M</given-names></name></person-group><article-title>Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype</article-title><source>Blood</source><year>1997</year><volume>90</volume><fpage>1109</fpage><lpage>1114</lpage><pub-id pub-id-type="pmid">9242542</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Edberg</surname><given-names>JC</given-names></name><name><surname>Redecha</surname><given-names>PB</given-names></name><name><surname>Bansal</surname><given-names>V</given-names></name><name><surname>Guyre</surname><given-names>PM</given-names></name><name><surname>Coleman</surname><given-names>K</given-names></name><name><surname>Salmon</surname><given-names>JE</given-names></name><name><surname>Kimberly</surname><given-names>RP</given-names></name></person-group><article-title>A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease</article-title><source>J Clin Invest</source><year>1997</year><volume>100</volume><fpage>1059</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">9276722</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sondermann</surname><given-names>P</given-names></name><name><surname>Huber</surname><given-names>R</given-names></name><name><surname>Oosthuizen</surname><given-names>V</given-names></name><name><surname>Jacob</surname><given-names>U</given-names></name></person-group><article-title>The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex</article-title><source>Nature</source><year>2000</year><volume>406</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">10917521</pub-id><pub-id pub-id-type="doi">10.1038/35018508</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warmerdam</surname><given-names>PA</given-names></name><name><surname>van de Winkel</surname><given-names>JG</given-names></name><name><surname>Vlug</surname><given-names>A</given-names></name><name><surname>Westerdaal</surname><given-names>NA</given-names></name><name><surname>Capel</surname><given-names>PJ</given-names></name></person-group><article-title>A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding</article-title><source>J Immunol</source><year>1991</year><volume>147</volume><fpage>1338</fpage><lpage>1343</lpage><pub-id pub-id-type="pmid">1831223</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parren</surname><given-names>PW</given-names></name><name><surname>Warmerdam</surname><given-names>PA</given-names></name><name><surname>Boeije</surname><given-names>LC</given-names></name><name><surname>Arts</surname><given-names>J</given-names></name><name><surname>Westerdaal</surname><given-names>NA</given-names></name><name><surname>Vlug</surname><given-names>A</given-names></name><name><surname>Capel</surname><given-names>PJ</given-names></name><name><surname>Aarden</surname><given-names>LA</given-names></name><name><surname>van de Winkel</surname><given-names>JG</given-names></name></person-group><article-title>On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2</article-title><source>J Clin Invest</source><year>1992</year><volume>90</volume><fpage>1537</fpage><lpage>1546</lpage><pub-id pub-id-type="pmid">1401085</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>AW</given-names></name><name><surname>Griffiths</surname><given-names>B</given-names></name><name><surname>Ponchel</surname><given-names>F</given-names></name><name><surname>Montague</surname><given-names>BM</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Gardner</surname><given-names>PP</given-names></name><name><surname>Gooi</surname><given-names>HC</given-names></name><name><surname>Situnayake</surname><given-names>RD</given-names></name><name><surname>Markham</surname><given-names>AF</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Isaacs</surname><given-names>JD</given-names></name></person-group><article-title>Fcgamma receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups</article-title><source>Arthritis Rheum</source><year>2000</year><volume>43</volume><fpage>2328</fpage><lpage>2334</lpage><pub-id pub-id-type="pmid">11037893</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(200010)43:10&#x0003c;2328::AID-ANR21&#x0003e;3.0.CO;2-Z</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>AW</given-names></name><name><surname>Keyte</surname><given-names>VH</given-names></name><name><surname>Babbage</surname><given-names>SJ</given-names></name><name><surname>Robinson</surname><given-names>JI</given-names></name><name><surname>Ponchel</surname><given-names>F</given-names></name><name><surname>Barrett</surname><given-names>JH</given-names></name><name><surname>Bhakta</surname><given-names>BB</given-names></name><name><surname>Bingham</surname><given-names>SJ</given-names></name><name><surname>Buch</surname><given-names>MH</given-names></name><name><surname>Conaghan</surname><given-names>PG</given-names></name><etal></etal></person-group><article-title>FcgammaRIIIA-158V and rheumatoid arthritis: a confirmation study</article-title><source>Rheumatology (Oxford)</source><year>2003</year><volume>42</volume><fpage>528</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">12649399</pub-id><pub-id pub-id-type="doi">10.1093/rheumatology/keg169</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kyogoku</surname><given-names>C</given-names></name><name><surname>Tsuchiya</surname><given-names>N</given-names></name><name><surname>Matsuta</surname><given-names>K</given-names></name><name><surname>Tokunaga</surname><given-names>K</given-names></name></person-group><article-title>Studies on the association of Fc gamma receptor IIA, IIB, IIIA and IIIB polymorphisms with rheumatoid arthritis in the Japanese: evidence for a genetic interaction between HLA-DRB1 and FCGR3A</article-title><source>Genes Immun</source><year>2002</year><volume>3</volume><fpage>488</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">12486608</pub-id><pub-id pub-id-type="doi">10.1038/sj.gene.6363921</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Radstake</surname><given-names>TR</given-names></name><name><surname>Petit</surname><given-names>E</given-names></name><name><surname>Pierlot</surname><given-names>C</given-names></name><name><surname>van de Putte</surname><given-names>LB</given-names></name><name><surname>Cornelis</surname><given-names>F</given-names></name><name><surname>Barrera</surname><given-names>P</given-names></name></person-group><article-title>Role of Fcgamma receptors IIA, IIIA, and IIIB in susceptibility to rheumatoid arthritis</article-title><source>J Rheumatol</source><year>2003</year><volume>30</volume><fpage>926</fpage><lpage>933</lpage><pub-id pub-id-type="pmid">12734884</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieto</surname><given-names>A</given-names></name><name><surname>Caliz</surname><given-names>R</given-names></name><name><surname>Pascual</surname><given-names>M</given-names></name><name><surname>Mataran</surname><given-names>L</given-names></name><name><surname>Garcia</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name></person-group><article-title>Involvement of Fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>2000</year><volume>43</volume><fpage>735</fpage><lpage>739</lpage><pub-id pub-id-type="pmid">10765917</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(200004)43:4&#x0003c;735::AID-ANR3&#x0003e;3.0.CO;2-Q</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>I</given-names></name><name><surname>Staub</surname><given-names>A</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name></person-group><article-title>Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme</article-title><source>Science</source><year>1999</year><volume>286</volume><fpage>1732</fpage><lpage>1735</lpage><pub-id pub-id-type="pmid">10576739</pub-id><pub-id pub-id-type="doi">10.1126/science.286.5445.1732</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wipke</surname><given-names>BT</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>McCarthy</surname><given-names>TJ</given-names></name><name><surname>Allen</surname><given-names>PM</given-names></name></person-group><article-title>Dynamic visualization of a joint-specific autoimmune response through positron emission tomography</article-title><source>Nat Immunol</source><year>2002</year><volume>3</volume><fpage>366</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">11896393</pub-id><pub-id pub-id-type="doi">10.1038/ni775</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>I</given-names></name><name><surname>Lee</surname><given-names>DM</given-names></name><name><surname>Goldbach-Mansky</surname><given-names>R</given-names></name><name><surname>Sumida</surname><given-names>T</given-names></name><name><surname>Hitchon</surname><given-names>CA</given-names></name><name><surname>Schur</surname><given-names>PH</given-names></name><name><surname>Anderson</surname><given-names>RJ</given-names></name><name><surname>Coblyn</surname><given-names>JS</given-names></name><name><surname>Weinblatt</surname><given-names>ME</given-names></name><name><surname>Brenner</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders</article-title><source>Arthritis Rheum</source><year>2003</year><volume>48</volume><fpage>944</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">12687536</pub-id><pub-id pub-id-type="doi">10.1002/art.10898</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schaller</surname><given-names>M</given-names></name><name><surname>Burton</surname><given-names>DR</given-names></name><name><surname>Ditzel</surname><given-names>HJ</given-names></name></person-group><article-title>Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease</article-title><source>Nat Immunol</source><year>2001</year><volume>2</volume><fpage>746</fpage><lpage>753</lpage><pub-id pub-id-type="pmid">11477412</pub-id><pub-id pub-id-type="doi">10.1038/90696</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Gaalen</surname><given-names>FA</given-names></name><name><surname>Toes</surname><given-names>RE</given-names></name><name><surname>Ditzel</surname><given-names>HJ</given-names></name><name><surname>Schaller</surname><given-names>M</given-names></name><name><surname>Breedveld</surname><given-names>FC</given-names></name><name><surname>Verweij</surname><given-names>CL</given-names></name><name><surname>Huizinga</surname><given-names>TW</given-names></name></person-group><article-title>Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><fpage>395</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">14872481</pub-id><pub-id pub-id-type="doi">10.1002/art.20028</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kassahn</surname><given-names>D</given-names></name><name><surname>Kolb</surname><given-names>C</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name><name><surname>Bochtler</surname><given-names>P</given-names></name><name><surname>Illges</surname><given-names>H</given-names></name></person-group><article-title>Few human autoimmune sera detect GPI</article-title><source>Nat Immunol</source><year>2002</year><volume>3</volume><fpage>411</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">11976712</pub-id><pub-id pub-id-type="doi">10.1038/ni0502-411b</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schubert</surname><given-names>D</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Zaiss</surname><given-names>D</given-names></name><name><surname>Jungblut</surname><given-names>PR</given-names></name><name><surname>Kamradt</surname><given-names>T</given-names></name></person-group><article-title>Autoantibodies to GPI and creatine kinase in RA</article-title><source>Nat Immunol</source><year>2002</year><volume>3</volume><fpage>411</fpage><pub-id pub-id-type="pmid">11976711</pub-id><pub-id pub-id-type="doi">10.1038/ni0502-411a</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Edworthy</surname><given-names>SM</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>McShane</surname><given-names>DJ</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>Cooper</surname><given-names>NS</given-names></name><name><surname>Healey</surname><given-names>LA</given-names></name><name><surname>Kaplan</surname><given-names>SR</given-names></name><name><surname>Liang</surname><given-names>MH</given-names></name><name><surname>Luthra</surname><given-names>HS</given-names></name><etal></etal></person-group><article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1988</year><volume>31</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">3358796</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>XM</given-names></name><name><surname>Arepally</surname><given-names>G</given-names></name><name><surname>Poncz</surname><given-names>M</given-names></name><name><surname>McKenzie</surname><given-names>SE</given-names></name></person-group><article-title>Rapid detection of the Fc gamma RIIA-H/R 131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED)</article-title><source>J Immunol Methods</source><year>1996</year><volume>199</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">8960098</pub-id><pub-id pub-id-type="doi">10.1016/S0022-1759(96)00164-0</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schubert</surname><given-names>D</given-names></name><name><surname>Maier</surname><given-names>B</given-names></name><name><surname>Morawietz</surname><given-names>L</given-names></name><name><surname>Krenn</surname><given-names>V</given-names></name><name><surname>Kamradt</surname><given-names>T</given-names></name></person-group><article-title>Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice</article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>4503</fpage><lpage>4509</lpage><pub-id pub-id-type="pmid">15034067</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muraki</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>I</given-names></name><name><surname>Chino</surname><given-names>Y</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>E</given-names></name><name><surname>Goto</surname><given-names>D</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Murata</surname><given-names>H</given-names></name><name><surname>Tsutsumi</surname><given-names>A</given-names></name><name><surname>Sumida</surname><given-names>T</given-names></name></person-group><article-title>Glucose-6-phosphate isomerase variants play a key role in the generation of anti-GPI antibodies: possible mechanism of autoantibody production</article-title><source>Biochem Biophys Res Commun</source><year>2004</year><volume>323</volume><fpage>518</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">15369782</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.08.123</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>PCR-RFLP analysis of the <italic>FCGR3A </italic>and <italic>FCGR2A </italic>genes. cDNA was amplified with primers and restriction digested using appropriate enzymes. Digested PCR products were visualized with ethidium bromide. <bold>(a) </bold><italic>FCGR3A </italic>gene and <bold>(b) </bold><italic>FCGR2A </italic>gene. ND, nondigested PCR product; RE, restriction enzyme.</p></caption><graphic xlink:href="ar1802-1"></graphic></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Population of anti-GPI antibody positive individuals, and <italic>FCGR3A </italic>and <italic>FCGR2A </italic>genotypes. The study included 187 patients with rheumatoid arthritis and 158 healthy Japanese individuals. The horizontal and vertical dotted lines represent the cutoff optical density values calculated from ELISA reactions of 158 healthy individuals for human recombinant GPI and rabbit native GPI, respectively. Individuals positive for both antibodies were considered anti-GPI antibody positive. Numbers in each graph represent the proportions of individuals positive for anti-GPI antibodies relative to the total number of individuals in that group. GPI, glucose-6-phosphate isomerase; HS, healthy subjects; RA, rheumatoid arthritis.</p></caption><graphic xlink:href="ar1802-2"></graphic></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Higher titres of anti-human and anti-rabbit GPI antibodies in <italic>FCGR3A</italic>-158V/V RA patients versus healthy individuals. In individuals homozygous for the <italic>FCGR3A </italic>high affinity V/V genotype (14 RA patients and 8 healthy individuals), both anti-human GPI antibodies and anti-rabbit GPI antibodies were significantly elevated in the RA group (<italic>P </italic>= 0.0027 and <italic>P </italic>= 0.0015 for anti-human GPI antibodies and anti-rabbit GPI antibodies, respectively, by Mann&#x02013;Whitney U-test). GPI, glucose-6-phosphate isomerase; RA, rheumatoid arthritis.</p></caption><graphic xlink:href="ar1802-3"></graphic></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Frequencies of <italic>FCGR3A </italic>and <italic>FCGR2A </italic>genotypes in patients with RA and positive and negative for anti-GPI antibodies</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="3"><italic>FCGR3A</italic>-158</td><td align="center" colspan="3"><italic>FCGR2A</italic>-131</td></tr><tr><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="center">FF low</td><td align="center">F/V</td><td align="center">VV high</td><td align="center">HH high</td><td align="center">H/R</td><td align="center">RR low</td></tr></thead><tbody><tr><td align="left">GPI<sup>+ </sup>RA (<italic>n </italic>= 23)</td><td align="center">10 (43.5)</td><td align="center">9 (39.1)</td><td align="center">4 (17.4)</td><td align="center">16 (69.6)</td><td align="center">6 (26.1)</td><td align="center">1 (4.3)</td></tr><tr><td align="left">GPI<sup>- </sup>RA (<italic>n </italic>= 164)</td><td align="center">86 (52.4)</td><td align="center">68 (41.5)</td><td align="center">10 (6.1)</td><td align="center">128 (78)</td><td align="center">29 (17.7)</td><td align="center">7 (4.3)</td></tr><tr><td align="left">GPI<sup>+ </sup>Control (<italic>n </italic>= 9)</td><td align="center">8(88.9)</td><td align="center">1 (11.1)</td><td align="center">0 (0)</td><td align="center">4 (44.4)</td><td align="center">5 (55.6)</td><td align="center">0 (0)</td></tr><tr><td align="left">GPI<sup>- </sup>Control (<italic>n </italic>= 149)</td><td align="center">83 (55.7)</td><td align="center">58 (38.9)</td><td align="center">8 (5.4)</td><td align="center">109 (73.2)</td><td align="center">40 (26.8)</td><td align="center">0 (0)</td></tr></tbody></table><table-wrap-foot><p>Data are expressed as number (percentage) of individuals. GPI, glucose-6-phosphate isomerase; high, high affinity genotype; low, low affinity genotype; RA, rheumatoid arthritis.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Alleic skewing of <italic>FCGR3A </italic>and <italic>FCGR2A </italic>in anti-GPI antibody positive healthy individuals</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Polymorphism</td><td align="left">Allele</td><td align="left">RA GPI<sup>+ </sup>(<italic>n </italic>= 46)</td><td align="left">Healthy GPI<sup>+ </sup>(<italic>n </italic>= 18)</td><td align="left"><italic>P </italic>(&#x003c7;<sup>2</sup>)</td><td align="left"><italic>P </italic>(Fisher's)</td><td align="left">OR (95% CI)</td></tr></thead><tbody><tr><td align="left"><italic>FCGR3A</italic>-158</td><td align="left">F</td><td align="left">29</td><td align="left">17</td><td align="left">0.012</td><td align="left">0.013</td><td align="left">0.10 (0.01&#x02013;0.82)</td></tr><tr><td></td><td align="left">V</td><td align="left">17</td><td align="left">1</td><td></td><td></td><td></td></tr><tr><td align="left"><italic>FCGR2A</italic>-131</td><td align="left">H</td><td align="left">38</td><td align="left">13</td><td align="left">0.35</td><td align="left">0.4902</td><td align="left">1.83 (0.51&#x02013;6.59)</td></tr><tr><td></td><td align="left">R</td><td align="left">8</td><td align="left">5</td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p><italic>P </italic>values are given for RA versus healthy individuals using a 2&#x000d7;2 contingency table. CI, confidence interval; Fisher's, Fisher's probability test; OR, odds ratio; RA, rheumatoid arthritis.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Genotype skewing of <italic>FCGR3A </italic>and <italic>FCGR2A </italic>gene polymorphisms in anti-GPI antibody positive healthy individuals</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Polymorphism</td><td align="left">Genotype</td><td align="left">RA GPI<sup>+ </sup>(<italic>n </italic>= 23)</td><td align="left">Healthy GPI<sup>+ </sup>(<italic>n </italic>= 9)</td><td align="left"><italic>P </italic>(&#x003c7;<sup>2</sup>)</td><td align="left"><italic>P </italic>(Fisher's)</td><td align="left">OR (95% CI)</td></tr></thead><tbody><tr><td align="left"><italic>FCGR3A</italic>-158</td><td align="left">FF</td><td align="left">10 (43.5%)</td><td align="left">8 (88.9%)</td><td align="left">0.019</td><td align="left">0.044</td><td align="left">0.09 (0.01&#x02013;0.89)</td></tr><tr><td></td><td align="left">FV/VV</td><td align="left">13(56.5%)</td><td align="left">1 (11.1%)</td><td></td><td></td><td></td></tr><tr><td align="left"><italic>FCGR2A</italic>-131</td><td align="left">HH</td><td align="left">16 (69.6%)</td><td align="left">4(44.4%)</td><td align="left">0.19</td><td align="left">0.24</td><td align="left">2.86 (0.58&#x02013;13.96)</td></tr><tr><td></td><td align="left">HR/RR</td><td align="left">7 (30.4%)</td><td align="left">5 (55.6%)</td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p><italic>P </italic>values are given for RA versus healthy individuals using a 2&#x000d7;2 contingency table. CI, confidence interval; Fisher's, Fisher's probability test; OR, odds ratio; RA, rheumatoid arthritis.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p><italic>FCGR3A </italic>and <italic>FCGR2A </italic>genotypes in rheumatoid factor positive and negative RA patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Polymorphism</td><td align="left">Genotype</td><td align="left">RA RF<sup>+ </sup>(n = 130)</td><td align="left">RA RF<sup>- </sup>(<italic>n </italic>= 57)</td><td align="left"><italic>P </italic>(&#x003c7;<sup>2</sup>)</td><td align="left">OR (95% CI)</td></tr></thead><tbody><tr><td align="left"><italic>FCGR3A</italic>-158</td><td align="left">FF</td><td align="left">66 (50.8%)</td><td align="left">30(52.6%)</td><td align="left">0.82</td><td align="left">0.93 (0.50&#x02013;1.73)</td></tr><tr><td></td><td align="left">FV/VV</td><td align="left">64(49.2%)</td><td align="left">27 (47.4%)</td><td></td><td></td></tr><tr><td align="left"><italic>FCGR2A</italic>-131</td><td align="left">HH</td><td align="left">103 (79.2%)</td><td align="left">42(73.7%)</td><td align="left">0.4</td><td align="left">1.36 (0.66&#x02013;2.82)</td></tr><tr><td></td><td align="left">HR/RR</td><td align="left">27 (20.8%)</td><td align="left">15 (26.3%)</td><td></td><td></td></tr></tbody></table><table-wrap-foot><p><italic>P </italic>values are given for RA RF<sup>+ </sup>versus RA RF<sup>- </sup>using a 2&#x000d7;2 contingency table. CI, 95% confidence interval; OR, odds ratio; RA, rheumatoid arthritis; RF, rheumatoid factor.</p></table-wrap-foot></table-wrap></sec></back></article> 